April 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
At the AACR 2024, Crescendo Biologics showcased early-stage findings for its primary investigational drug, CB307, while also revealing CB699, their inaugural dual-functioning immune cell attractor.
The study reveals a structure-guided strategy for biased drug optimization and has led to the development of two biased agonist drug candidates targeting the APLNR receptor.
April 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Nurix Therapeutics Announces Initial Clinical Signs of Brain Activity for NX-5948, an Orally Administered Compound That Crosses Blood-Brain Barrier and Targets BTK for Treating B Cell Cancers.
Foghorn Therapeutics Unveils Novel Early-Stage Research Findings for Unique BRM Targeted Inhibitor FHD-909 and Distinct CBP & EP300 Degrader Initiatives in Cancer Treatment.